Montauk Renewables (MNTK) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
13 Nov, 2025Executive summary
Q3 2025 revenues were $45.3 million, down 31.3% year-over-year, mainly due to lower RIN sales and a 31.4% drop in realized RIN prices.
Net income for Q3 2025 was $5.2 million, a decrease of 69.5% from Q3 2024.
Adjusted EBITDA for Q3 2025 was $12.8 million, down 56.5% year-over-year.
RNG production increased 3.8% year-over-year to 1.4 million MMBtu, with higher output at Apex and Rumpke facilities.
Renewable electricity production rose 7.3% to 44,000 MWh, with Bowerman facility contributing most of the increase.
Financial highlights
Q3 2025 total operating revenues: $45.3 million (down 31.3% YoY); nine months: $133.0 million (down 10.2% YoY).
Q3 2025 operating income: $4.4 million, down 80.4% year-over-year.
Average realized RIN price was $2.29, down 31.4% from $3.34 in Q3 2024.
Operating and maintenance expenses for RNG facilities increased 10.6% to $13.9 million.
Cash and cash equivalents at September 30, 2025, were $6.8 million, down from $55.0 million a year earlier.
Outlook and guidance
2025 RNG production expected between 5.8–6.0 million MMBtu, with revenues of $150–$170 million.
Renewable electricity production for 2025 projected at 175,000–180,000 MWh, with revenues of $17–$18 million.
Ongoing development projects include Bowerman, Montauk Ag Renewables, and EENA CO2, with 2025 development capex expected between $90 million and $120 million.
Montauk Ag Renewables project in North Carolina expected to commence significant revenue generation in 2026, with a capital investment of $180–$220 million.
Regulatory changes and market volatility in RIN and LCFS pricing expected to impact future results.
Latest events from Montauk Renewables
- Net income plunged on flat revenue as RIN prices fell, but 2026 guidance expects growth.MNTK
Q4 202512 Mar 2026 - Q2 revenue dropped 18.6% on delayed RIN sales, but 2024 guidance and project pipeline remain strong.MNTK
Q2 20241 Feb 2026 - Q3 2024 revenue up 18.4% and net income up 31.8%, but project delays persist.MNTK
Q3 202414 Jan 2026 - Net income fell 34.9% to $9.7M on flat revenue, with 2025 RNG revenue guidance at $150–$170M.MNTK
Q4 202426 Dec 2025 - Director elections, auditor ratification, and strategic growth initiatives highlight the 2025 meeting.MNTK
Proxy Filing1 Dec 2025 - Shareholders to elect two directors and ratify Grant Thornton LLP as auditor at the annual meeting.MNTK
Proxy Filing1 Dec 2025 - Revenue up 9.8%, but net loss and regulatory delays challenge outlook; major capex planned.MNTK
Q1 202526 Nov 2025 - Q2 2025 revenue rose 4.1% but net loss widened on lower RIN prices and higher costs.MNTK
Q2 202523 Nov 2025